Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Position Boosted by Suncoast Equity Management

Suncoast Equity Management raised its position in shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) by 109.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,194 shares of the company’s stock after buying an additional 26,803 shares during the quarter. Suncoast Equity Management’s holdings in Telomir Pharmaceuticals were worth $329,000 at the end of the most recent quarter.

Separately, Beaird Harris Wealth Management LLC boosted its holdings in Telomir Pharmaceuticals by 212.9% in the second quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock worth $70,000 after purchasing an additional 9,950 shares during the period.

Telomir Pharmaceuticals Trading Down 4.9 %

Shares of Telomir Pharmaceuticals stock traded down $0.23 during trading hours on Monday, reaching $4.47. The company’s stock had a trading volume of 16,627 shares, compared to its average volume of 80,321. Telomir Pharmaceuticals, Inc. has a one year low of $3.11 and a one year high of $20.72. The company’s 50 day simple moving average is $5.50 and its 200 day simple moving average is $5.51.

Telomir Pharmaceuticals (NASDAQ:TELO) last issued its earnings results on Tuesday, August 13th. The company reported ($0.05) earnings per share (EPS) for the quarter.

Telomir Pharmaceuticals Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.